Published in Can J Gastroenterol on January 01, 2002
Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ (2007) 2.15
Using a systematic review in clinical decision making: a pilot parallel, randomized controlled trial. Implement Sci (2015) 0.84
Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers. Can J Gastroenterol (2007) 0.75
Evidence-based medicine: a resource for all. Can J Gastroenterol (2002) 0.75
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ (2010) 3.60
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol (2013) 2.27
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol (2008) 2.24
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol (2011) 2.15
A prospective cohort study found that provider and information continuity was low after patient discharge from hospital. J Clin Epidemiol (2010) 1.95
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol (2008) 1.94
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens (2003) 1.76
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care (2005) 1.53
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology (2008) 1.53
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care (2011) 1.30
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
The independent association of provider and information continuity on outcomes after hospital discharge: implications for hospitalists. J Hosp Med (2010) 1.13
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results. Card Electrophysiol Rev (2003) 1.05
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1. Inflamm Bowel Dis (2016) 1.01
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol (2012) 0.97
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes (2013) 0.93
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev (2008) 0.93
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis (2007) 0.91
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res (2007) 0.89
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes (2010) 0.89
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care (2014) 0.86
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol (2004) 0.85
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol (2010) 0.85
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori. Can J Gastroenterol (2003) 0.83
Patient-directed intelligent and interactive computer medical history-gathering systems: a utility and feasibility study in the emergency department. Int J Med Inform (2006) 0.82
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology (2012) 0.82
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs (2008) 0.81
Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis (2015) 0.79
A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatr Diabetes (2011) 0.79
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis (2010) 0.78
WITHDRAWN: Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2015) 0.78
Diagnosing technical competence in six bedside procedures: comparing checklists and a global rating scale in the assessment of resident performance. Acad Med (2015) 0.77
Research of the holiday kind. Stableford: equitable golf-scoring system or quality-of-life measure? CMAJ (2002) 0.75
In response. J Thorac Oncol (2013) 0.75
Managing hypertension: evidence supporting the 2013/2014 recommendations of the Canadian Hypertension Education Program. CMAJ (2014) 0.75
Dietary sodium and cardiovascular outcomes: a rational approach. Can J Cardiol (2007) 0.75
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clin Breast Cancer (2007) 0.75
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res (2006) 0.75
How Attending Physician Preceptors Negotiate Their Complex Work Environment: A Collective Ethnography. Acad Med (2017) 0.75
Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. Anesth Analg (2017) 0.75